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Background : Prognosis of advanced hepatocellu1ar carcinoma (HCC) is extremely poor, and no standard therapy 
is available yet. Interferon (IFN) is a promising drug for prevention of HCC, and its combinations with 
chemotherapeutic agents might be effective for advanced HCCs. However, little is known about the underlying 
mechanism of the response of HCC cells to IFN. Herein, 1 studied the mechanism of direct antitumor effect of 
type 1 IFNs on HCC ce1l1ines and mouse xenograft models. 
Materia1s and methods : The mechanistic study of antitumor effects of type 1 IFNs (natural IFN-α ， IFN- )ﾟ was 
conducted on three HCC cell 1ines (HuH7, PLC/PRF/5, HLE). Growth-inhibitory assays were performed to 
study the antiproliferative effect of IFNs and each of their combinations with anticancer drugs (5-fluorouracil, 
cisplatin, doxorubicin) ﾍn vﾍtro. Evaluation of drugs interactions was done using isobologram analysis. 
Expressions of IFN alpha receptors (IFNAR) and base or phosphorylated forms of signal transducer and 
activator of transcription (STAT) proteins were examined by Western blot. To evaluate the impact of IFNAR2 
in the effect of IFNs, neutralizing assay using anti-IFNAR2 antibody was employed. Mouse xenograft models 
were used to determine the effectiveness of IFN-αor IFN-ﾟ  treatments on HCC tumor growth. 
Results : The celllines differed in their sensitivities to the IFN s ; PLC/PRF/5 was the most sensitive to the IFN s, 
while HuH7 and HLE were resistant. From IFN signaling components, IFN alpha receptor (IFNAR) 2c was 
highly expressed only in IFN-sensitive PLC/PRF/5 cells, and the expression levels of STATl and 3 (especially 
those ß ・isoforms) in these cells were higher than in the other cell lines. Pre-treatment with anti-IFNAR2 
antibody dose-dependently blocked the antiproliferative effect of the IFNs. When the cells were assayed with 
various doses of IFNs, IFN signal transduction (phosphorylated STATl and 3, but not STAT2) was high in 
PLC/PRF/5 than in other cells. 
IFN:-ﾟ  showed a significantly stronger growth-inhibitory effect than IFN-αon HuH7 cells. This effect has 
resulted from intense and expanded signal transduction induced by IFN-ﾟ  (1.6・ 10.6-fold higher depending on 
IFN doses). By neutralizing assay, a difference in binding of the IFNs to IFNAR2 was found, as well as for 
suppression of the effects of IFN -ﾟ  required more antibody than for IFN-α. 
N ext, 1 examined the possibility of synergic action of IFN-αor IFN -ﾟ  with anticancer drugs ; IFN-αshowed 
synergistic effects with 5-fluorouracil or with doxorubicin on PLC/PRF/5 cells only, whereas for IFN-ﾟ  , 
cooperative synergistic effects were observed when combined with 5-fluorouracil or cisplatin on HuH7 and 
PLC/PRF/5 celllines. 
In nude mouse tumor xenograft models, treatment with IFN-ﾟ  (2 x 104 IU/animal thrice a week) significantly 
suppressed tumor volume relative to vehicle injection, in mice bearing HuH7 and PLC/PRF/5 tumors 
(respectively by 47% and 31%), whereas same administration ofIFN-αshowed weak growth-inhibition. 
Conclusion : The results suggest that IFN signaling (expression of IFNAR2c and activation of STAT1 and 3) 
mediates the antitumor effects of type 1 IFNs in HCC cells. The spectra of antiproliferative activity of IFN-ﾟ  
and its synergistic effect when combined with anticancer drugs would be more potent than those with IFN-α. 




が、肝細胞癌に対する IFN の抗腫療効果の作用機序は、十分に解明されていない。本研究では、 IFN の抗腫療効果
の作用機序および抗癌剤との併用効果について検討した。 3 種類のヒト肝細胞癌株を用いた実験では、 IFN の抗腫蕩
効果は、そのシグナル伝達を担う、 IFNAR2c と STAT1 、 3 の発現量によって制御されていた。 IFNAR2c の中和抗体
を用いた中和反応試験では、濃度依存性に抗腫療効果の抑制が認められ、さらに IFN- ß では、 IFN-α よりも高濃度
の中和抗体を抗腫虜効果の抑制に必要とした。また、 IFN- ß は、 IFN-α よりも 5齢、増殖抑制効果を示し、抗癌剤との
併用においても、多くの組み合わせで相乗効果が認められた。本研究は、肝細胞癌に対する IFN の抗腫療効果におい
て、 IFN の受容体とそのシグナル伝達が関与することを示し、さらには、 IFN-ß が IFN-α よりも単剤もしくは抗癌
剤との併用においても強い増殖抑制効果を示しすことを明らかにしたものであり、今後臨床応用が期待され、学位の
授与に値すると考える。
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